1-(2-hydroxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one | 56983-72-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2-hydroxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one
• 英文别名: (2-hydroxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one；2-(2-hydroxy-benzoyl)-5-methyl-1,2-dihydro-pyrazol-3-one；2-(2-hydroxybenzoyl)-5-methyl-4H-pyrazol-3-one
• CAS: 56983-72-3
• 化学式: C₁₁H₁₀N₂O₃
• mdl: MFCD00519044
• 分子量: 218.212
• InChiKey: WVQMNFHYJBWNDO-UHFFFAOYSA-N

物化性质

• 熔点：
  136 °C(Solv: methanol (67-56-1))
• 沸点：
  375.1±44.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  70
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2-hydroxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one 在 sodium acetate 作用下， 以 溶剂黄146 为溶剂， 生成 (2-Hydroxyphenyl)-[7-(4-methoxyphenyl)-5-methyl-1,3,4,8-tetrazatricyclo[7.4.0.02,6]trideca-2(6),4,8,10,12-pentaen-3-yl]methanone
  参考文献：
  名称：

  Khan, Mukhtar Hussain; Haque, Raziul; Agrawal, Taruna, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1999, vol. 38, # 4, p. 452 - 456

  摘要：

  DOI：
• 作为产物：
  描述：

  水杨酰肼 以 1,4-二氧六环 、 邻二氯苯 为溶剂， 反应 9.0h， 生成 1-(2-hydroxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one
  参考文献：
  名称：

  Hogale; Pawar, Journal of the Indian Chemical Society, 1989, vol. 66, # 2, p. 135 - 138

  摘要：

  DOI：

文献信息

• Synthesis and Biological Evaluation of Some Heterocyclic Compounds from Salicylic Acid Hydrazide
  作者：E. M. Sarshira、N. M. Hamada、Y. M. Moghazi、M. M. Abdelrahman

  DOI：10.1002/jhet.2516

  日期：2016.11

  example, cyclization of hydrazide hydrazone 3 derived from 2‐hydroxybenzohydrazide 2 with acetic anhydride or concentrated sulfuric acid gave 1,3,4‐oxadiazole derivatives 4–5. On the other hand, direct cyclization of 2‐hydroxy benzohydrazide 2 with one carbon cyclizing agent gave a new derivative of 1,3,4‐oxadiazole 7, 8, 9, 10, 11. Heating of hydrazide hydrazone 3 with thioglycolic acid in pyridine gave

  从2-羟基苯甲酰肼开始制备了各种杂环化合物；例如，酰肼腙环化3由2- hydroxybenzohydrazide衍生2用乙酸酐或浓硫酸，得到1,3,4-恶二唑衍生物4 - 5。在另一方面，2-羟基苯甲酰肼的环化直接2与一个碳环化剂得到的1,3,4-恶二唑的新衍生7，8，9，10，11。用吡啶中的巯基乙酸对酰肼3进行加热，得到噻唑烷酮12。当2-羟基苯甲酰肼2与脂肪族羧酸（例如甲酸或乙酸）反应时，得到相应的N-甲酰基或N-乙酰基衍生物6。随后在吡啶中使用五硫化二磷对6进行环化，得到1,3,4-噻二唑13。2-羟基苯并肼与乙酰乙酸乙酯的环化反应得到吡唑啉酮衍生物14。最后，当在35％HCl中用硫氰酸铵处理酰肼2的乙醇溶液时，得到硫代氨基脲15。后续治疗15用浓硫酸或10％氢氧化钠溶液分别制得5-氨基-1,3,4-噻二唑16和1,2,4-三唑17。使用1 H NMR，IR光谱和元素分析确认了所有
• Novel pyrazoles and pyrazolo[1,2- a ]pyridazines as selective COX-2 inhibitors; Ultrasound-assisted synthesis, biological evaluation, and DFT calculations
  作者：Nagat Ghareb、Hosam A. Elshihawy、Mohamed M. Abdel-Daim、Mohamed A. Helal

  DOI：10.1016/j.bmcl.2017.04.020

  日期：2017.6

  devoid of ulcerogenic activity. Herein, we report the design and synthesis of a series of pyrazoles and pyrazolo[1,2-a]pyridazines with selective COX-2 inhibitory activity and in vivo anti-inflammatory effect. Both series were accessed through acid-catalyzed ultrasound-assisted reactions. The most active compounds in this study are two novel molecules, 11 and 16, showing promising selectivity and decent

  COX-2是一种介导炎症反应的诱导酶。COX-2的选择性靶向可用于开发无溃疡活性的抗炎药。在这里，我们报告设计和合成一系列具有选择性COX-2抑制活性和体内抗炎作用的吡唑和吡唑并[1,2-a]哒嗪。通过酸催化的超声辅助反应可以访问两个系列。这项研究中活性最高的化合物是两个新分子11和16，分别显示出有希望的选择性和16.50和20.1nM的适度IC50。这些化合物也停靠在COX-2酶的晶体结构（PDB ID：3LN1）中，以了解其结合方式。最后，使用DFT方法计算了化合物11和塞来昔布的Mulliken电荷和静电表面电势，以深入了解该化合物活性的分子决定因素。这些结果可能导致开发具有改进的选择性的新型COX-2抑制剂。
• NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION
  申请人：Neamati Nouri

  公开号：US20090093489A1

  公开（公告）日：2009-04-09

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.

  新型化合物用于治疗癌症和与血管生成功能相关的疾病。还公开了制备这些化合物的方法、含有这些化合物的药物组合物和包装产品、使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关的疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法、监测治疗的方法、基因表达谱分析的方法以及调节细胞生长、细胞周期、细胞凋亡或基因表达的方法。
• Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function
  申请人：Neamati Nouri

  公开号：US20100120781A1

  公开（公告）日：2010-05-13

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.

  该专利涉及新型化合物，用于治疗癌症和与血管生成功能相关的疾病。还公开了制备这些化合物的方法，含有这些化合物的药物组合物和包装产品，使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关的疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法，监测治疗的方法，基因表达谱分析的方法，以及细胞生长、细胞周期、凋亡或基因表达的调节方法。
• Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function
  申请人：NEAMATI Nouri

  公开号：US20110034472A1

  公开（公告）日：2011-02-10

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.

  新型化合物用于治疗癌症和与血管生成功能相关的疾病。还公开了制备这些化合物的方法，含有这些化合物的药物组合物和包装产品，使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关的疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法，监测治疗的方法，基因表达谱分析的方法，以及调节细胞生长、细胞周期、凋亡或基因表达的方法。